Adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-...

Dr Mariana Chavez Mac Gregor speaks to ecancer as part of SABCS 2022 about results from a phase III randomised, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer.
She explains that 2000 patients were randomised 1:1 to receive either placebo or 1 year of everolimus in addition to physicians choice adjuvant endocrine therapy.
Dr Mac Gregor reports that after almost 5 years of follow up that the addition of everolimus did not improve invasive disease free survival or overall survival.
She adds that an exploratory analysis observed that amongst premenopausal patients there was a statistically significant improvement in invasive disease free survival or overall survival with the addition of adjuvant everolimus.